Cullinan’s deal for T cell engager from China; Kardigan buys late-stage heart drugnews2025-06-05T14:38:32+00:00June 5th, 2025|Endpoints News|
Vigil drug fails a Phase 2; Merus aims to raise $300Mnews2025-06-04T14:25:49+00:00June 4th, 2025|Endpoints News|
Vera redraws the terms of up to $500M credit facility; Trevi aims to raise $100Mnews2025-06-03T14:32:36+00:00June 3rd, 2025|Endpoints News|
Sanofi pays out two STAT6 milestones; Theravance sells more Trelegy royaltiesnews2025-06-02T14:37:51+00:00June 2nd, 2025|Endpoints News|
Roche’s 96-week data for multiple sclerosis drug; ZymeWorks claims $20M milestonenews2025-05-30T14:15:53+00:00May 30th, 2025|Endpoints News|
Taysha’s pivotal trial plans; Keros to stop work on PAH drug, lay off 45% of staffnews2025-05-29T15:13:34+00:00May 29th, 2025|Endpoints News|
Veru’s obesity drug roughly as safe as Wegovy; Keros’ board fightnews2025-05-28T14:17:06+00:00May 28th, 2025|Endpoints News|
ITM reveals up to $262M debt financing; Caris Life Sciences to go publicnews2025-05-27T14:31:03+00:00May 27th, 2025|Endpoints News|
GLP-1s may cut cancer risk; Gyre’s stock falls after hep B data and offeringnews2025-05-23T14:30:46+00:00May 23rd, 2025|Endpoints News|
Moderna pulls application for Covid-flu shot; Another IPO in Hong Kongnews2025-05-21T14:40:36+00:00May 21st, 2025|Endpoints News|
